Global Breast Cancer Screening Market was US$ 1.64 Billion in 2022
Global Breast Cancer Screening Market will reach US$ 2.12 Billion in 2028, according to the publisher. Breast cancer screening can detect cancer early, even before any symptoms are present. Early detection is vital because it allows for more effective treatment options and increases the chances of a successful outcome. When breast cancer is detected early, more treatment options are available, including less invasive treatments and the possibility of breast-conserving surgery. In addition, breast cancer screening is cost-effective, as the cost of screening is significantly lower than that of treating advanced breast cancer.
Breastcancer.org's 2022 update projects that in the United States, 287,850 individuals received a diagnosis of invasive breast cancer, and an additional 51,400 individuals were diagnosed with non-invasive (in situ) breast cancer.
Breast cancer screening markets shall experience a CAGR of 5.26% from 2022 to 2028
The demand for breast cancer screening services has been increasing due to the rising incidence of breast cancer worldwide. According to the World Health Organization (WHO), breast cancer is the most prevalent type of cancer globally, with over 2.3 million new cases. A growing awareness has fuelled this rise in demand for screening services among women about the importance of breast cancer screening. As a result, women are encouraged to undergo screening through various campaigns, educational programs, and advocacy groups. Additionally, the aging of the population has also played a role in the increased demand for breast cancer screening services, as frequent diagnosis of breast cancer is common in older women.
Governments have implemented screening programs and policies to increase access to breast cancer screening, particularly for underserved populations. In addition, technological advancements have led to the development of more accurate and less invasive screening methods, such as digital mammography, breast ultrasound, and magnetic resonance imaging (MRI), which have improved the detection of breast cancer. For instance, in March 2022, LifeCell launched Breast Screen Panel, a comprehensive genetic screening test assessing women's risk of breast cancer. Hence, the market value for the global breast cancer screening market was US$ 1.64 Billion in 2022.
Increased Awareness, Technological Advancements, and Government Initiatives have led to the growing demand for Breast Cancer Screening Services in India
Countries present in the breast cancer screening market are the United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, Netherlands, New Zealand, Australia, United States, Canada, Japan, Korea, Singapore, India, Thailand, Malaysia, China, Brazil, South Africa, United Arab Emirates, Saudi Arabia, and Rest of World. Increasing disposable income in India has allowed more individuals to afford breast cancer screening services, awareness campaigns, and government initiatives, raising women's awareness about the importance of breast cancer screening and improving access to screening services, particularly for underserved populations. In addition, government initiatives such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) and the National Health Mission (NHM) have improved access to breast cancer screening in India.
In China, improved access to healthcare services, including breast cancer screening, can be attributed to the country's recent increase in healthcare spending. Additionally, the Chinese government has launched various initiatives to improve access to breast cancer screening, focusing on underserved populations. An example of such an initiative is the National Breast Cancer Screening Program, which offers free breast cancer screening to women living in rural areas.
High Incidence of Breast Cancer in the United States has increased the emphasis on Breast Cancer Screening
Based on the Mammography breast cancer screening, there are 24 divisions - United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, Netherlands, New Zealand, Australia, United States, Canada, Japan, Korea, Singapore, India, Thailand, Malaysia, China, Brazil, South Africa, United Arab Emirates, Saudi Arabia, and Rest of World. Health insurance plans cover mammography, making it more accessible and affordable. In addition, advanced mammography technology has improved the accuracy of screening. The government has implemented policies to increase access to mammography, including initiatives to achieve 'zero fatalities from breast cancer' by 2030, as announced by the National Breast Cancer Foundation, with USD 12.4 Million in funding for 20 research initiatives.
Private Healthcare Sector in Brazil Embraces Advanced Breast Cancer Screening Technologies Amid Growing Awareness among Women.
The countries where MRI breast cancer screening is prevalent are the United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, Netherlands, New Zealand, Australia, United States, Canada, Japan, Korea, Singapore, India, Thailand, Malaysia, China, Brazil, South Africa, UAE, Saudi Arabia, and Rest of World. The private healthcare sector in Brazil has been investing in advanced breast cancer screening technologies, including MRI, to provide more accurate and effective screening services. Furthermore, there has been a growing awareness among women in Brazil about the importance of breast cancer screening, driven by campaigns, educational programs, and advocacy groups.
China shall have the Highest Share in the Ultrasound Screening Industry
United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, Netherlands, New Zealand, Australia, United States, Canada, Japan, Korea, Singapore, India, Thailand, Malaysia, China, Brazil, South Africa, UAE, Saudi Arabia, and Rest of World, is the different countries in the ultrasound breast cancer screening market. Ultrasound screening is safe and effective, particularly for younger women and women with dense breast tissue. The Chinese government has implemented initiatives to increase access to breast cancer screening, including promoting ultrasound screening as a primary screening method.
Additionally, the development and adoption of advanced ultrasound technology have improved the accuracy and effectiveness of ultrasound screening in detecting breast cancer.
There has been a growing emphasis on using ultrasound screening as a complement to mammography, particularly for women with dense breast tissue leading to increased adoption and utilization of ultrasound screening in the United States. Moreover, the United States has been a leader in developing and adopting advanced ultrasound technology, including 3D and 4D ultrasound, improving the accuracy and effectiveness of ultrasound screening in detecting breast cancer.
Key Players Analysis
AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc are significant companies competing in Breast Cancer Screening Market.
In June 2022, Walmart signed a general merchandise supplier agreement with Biomerica, Inc to sell the Aware Breast Self-Exam device in its retail system.
The report titled “Global Breast Cancer Screening Market Global Forecast by breast cancer screening (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, Netherlands, New Zealand, Australia, United States, Canada, Japan, Korea, Singapore, India, Thailand, Malaysia, China, Brazil, South Africa, UAE, Saudi Arabia, and ROW), Mammography screening (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, Netherlands, New Zealand, Australia, United States, Canada, Japan, Korea, Singapore, India, Thailand, Malaysia, China, Brazil, South Africa, UAE, Saudi Arabia, and ROW), MRI Screening (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, Netherlands, New Zealand, Australia, United States, Canada, Japan, Korea, Singapore, India, Thailand, Malaysia, China, Brazil, South Africa, UAE, Saudi Arabia, and ROW) Ultrasound Screening (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, Netherlands, New Zealand, Australia, United States, Canada, Japan, Korea, Singapore, India, Thailand, Malaysia, China, Brazil, South Africa, UAE, Saudi Arabia, and ROW), Company Analysis (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc)' provides a detailed analysis of Global breast cancer screening Market.
Breast Cancer Screening- Market breakup of 24 Countries:
1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Switzerland
7. Norway
8. Netherlands
9. New Zealand
10. Australia
11. United States
12. Canada
13. Japan
14. Korea
15. Singapore
16. India
17. Thailand
18. Malaysia
19. China
20. Brazil
21. South Africa
22. United Arab Emirates
23. Saudi Arabia
24. Rest of World
Mammography Screening - Market breakup from 24 Viewpoints:
1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Switzerland
7. Norway
8. Netherlands
9. New Zealand
10. Australia
11. United States
12. Canada
13. Japan
14. Korea
15. Singapore
16. India
17. Thailand
18. Malaysia
19. China
20. Brazil
21. South Africa
22. United Arab Emirates
23. Saudi Arabia
24. Rest of World
MRI Screening- Market breakup from 24 Viewpoints:
1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Switzerland
7. Norway
8. Netherlands
9. New Zealand
10. Australia
11. United States
12. Canada
13. Japan
14. Korea
15. Singapore
16. India
17. Thailand
18. Malaysia
19. China
20. Brazil
21. South Africa
22. United Arab Emirates
23. Saudi Arabia
24. Rest of World
Ultrasound Screening- Market breakup from 24 Viewpoints:
1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Switzerland
7. Norway
8. Netherlands
9. New Zealand
10. Australia
11. United States
12. Canada
13. Japan
14. Korea
15. Singapore
16. India
17. Thailand
18. Malaysia
19. China
20. Brazil
21. South Africa
22. United Arab Emirates
23. Saudi Arabia
24. Rest of World
Company has been covered from 3 Viewpoints:
- Overview
- Recent Development
- Revenue
Company Analysis:
1. AstraZeneca
2. Novartis
3. Sanofi
4. Pfizer
5. Bayer AG
6. GlaxoSmithKline plc
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary
Companies Mentioned
- AstraZeneca
- Novartis
- Sanofi
- Pfizer
- Bayer AG
- GlaxoSmithKline plc
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 450 |
| Published | April 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 1.64 Billion |
| Forecasted Market Value ( USD | $ 2.13 Billion |
| Compound Annual Growth Rate | 4.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 6 |
Related Reports
Breast Cancer Screening Market by Technology, Product, End User - Global Forecast 2025-2030
- Report
- 189 Pages
- Global
